1Khan MA,Moeez S,Akhtar S. T-regulatory cell-mediated immunetolerance as a potential immunotherapeutic strategy to facilitategraft survival[J]. Blood Transfus, 2013,11 (3): 357-363.
2Sagoo P,Lombardi G, Lechler RI. Relevance of regulatory T cellpromotion of donor-specific tolerance in solid organ transplantation[J]. Front Immunol, 2012, 3: 184.
3Fehr T, Sykes M. Clinical experience with mixed chimerism toinduce transplantation tolerance [ J ] . Transpl Int,2008,21(12): 1118-1135.
4Mathew JM,Leventhal JH,Miller J. Microchimerism in promotinggraft acceptance in clinical transplantation[ J]. Curr Opin OrganTransplant, 2011, 16 (4): 345-352.
5Scandling JD,Busque S,Shizuru JA, et al. Induced immunetolerance for kidney transplantation [ J]. N Engl J Med, 2011,365 (14) : 1359-1360.
6Matsushita T, Horikawa M,Iwata Y,et al. Regulatory B cells(B10 cells) and regulatory T cells have independent roles incontrolling experimental autoimmune encephalomyelitis initiationand late-phase immunopathogenesis [ J ]. J Immunol, 2010,185(4): 2240-2252.
7Chen JC, Kuo ML, Ou LS, et al. Characterization of toleranceinduction through prenatal marrow transplantation : the requirementfor a threshold level of chimerism to establish rather than maintainpostnatal skin tolerance [ J ]. Cell Transplant, 2010,19 (12):1609-1622.
9van den Hoogen MW, Hilbrands LB. Use of monoelonal antibodies in renal transplantation. Immunotherapy, 2011, 3 (7) : 871-880.
10Gabardi S, Martin ST, Roberts KL, et al. Induction immunosuppressive therapies in renal transplantation. Am J Health Syst Pharm, 2011, 68(3): 211-218.
1Ouellette AJ Paneth cell alpha-defensins in enteric innate immunity[J]. Cell Mol Life Sci, 2011, 68 (13) : 2215-2229. doi: 10. 1007/s00018-011-0714-6.
2Rohrl J, Yang D, Oppenheim JJ, et al. Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2[J]. J Immunol, 184(12) : 6688-6694. doi: 10. 4049/jimmunol. 0903984.
3Mariani M, Lang R, Binda E, et al. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 eells[J].Eur J Immunol, 2004, 34(1): 231-240.
4Moser B, Wolf M, Walz A, et al. Chemokines: multiple levels of leukocyte migration control [J]. Trends Immunol, 2004, 25(2) : 75-84.
5Thelen M, Thelen S. CXCR7, CXCR4 and CXCL12: an eccentric trio? [J]. J Neuroimmunol, 2008, 198 (1-2) : 9-13. doi: 10. 1016/j. jneuroim. 2008.04. 020.
6Struyf S, Burdick MD, Proost P, et al. Platelets release CXCIAL1, a nonallelic variant of the chemokine platelet factor-4/CXCIA and potent inhibitor of angiogenesis[J]. Circ Res,2004, 95(9): 855-857.
7Schmutz C, Cartwright A, Williams H, et al. Monocytes/ macmphages express chemokine receptor CCR9 in rheumatoid arthritis and OEL25 stimulates their differentiation[J]. Arthritis Res Ther,2010, 12(4): R161. doi: 10. 1186/ar3120.
8Johnson-Holiday C, Singh R, Johnson EL, et al. CCR9- CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PBK-dependent and FAK-independent fashion[J]. World J Surg Oncol,2011, 9: 46. doi: 10. 1186/1477-7819-9-46.
9Apostolaki M, Manoloukos M, Roulis M, et al. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/ CCR9 in modeled TNF-dependent Crohn's disease [J]. Gastroenterology,2008, 134(7): 2025-2035. doi: 10. 1053/j. gastro. 2008. 02. 085.
10van de Berg PJ, Yong SL, Koch SD, et al. Characteristics of alloreactive T cells measured before renal transplantation[J]. Clin Exp Immunol, 2012,168(2): 241-250. doi: 10. 1111/j. 1365-2249. 2011. 04551. x.
